Mergers & Acquisitions ·
On September 8, 2026, Jin Medical International Ltd. entered into a VIE Control Master Acquisition Agreement to…
ZJYLJin Medical International Ltd.
On September 8, 2026, Jin Medical International Ltd. entered into a VIE Control Master Acquisition Agreement to acquire contractual control over Huaxia Qiying and its subsidiaries for aggregate consideration of US$159,415,729. The Company will issue 71,282,488 Class A ordinary shares as primary consideration. Concurrently, the Company transferred investment assets valued at US$4,194,167 and RMB119,079,718 to the Seller Controlling Person and executed agreements transferring an 80% equity interest in Zhongjin Kangma. The transaction includes a financial advisory fee of US$15,941,572.90 payable in shares at $1.88 per share. Closing is subject to customary conditions including Nasdaq notification and PRC legal clearance. Jin Medical International Ltd. operates in the healthcare sector, focusing on elderly-care and rehabilitation products.